You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

AbstractFullPdf
Nov 2021287030
Dec 20216009
Jan 202238011
Feb 202250014
Mar 202217207
Apr 20225006
May 202256011
Jun 202240011
Jul 20224003
Aug 20224601
Sep 20222805
Oct 20222007
Nov 20222003
Dec 20222801
Jan 20233205
Feb 20231804
Mar 20231602
Apr 20232003
May 20232201
Jun 20233002
Jul 20232207
Aug 20234204
Sep 2023802
Oct 20233002
Nov 20234001
Dec 20233602
Jan 20241403
Feb 20242606
Mar 20241805
Apr 202410011
May 20242803
Jun 20242401
Jul 20242603
Aug 20241204
Total14090190